With CE Mark for Glaucoma Microsensor in Pocket, Implandata Looks to US

With CE Mark for Glaucoma Microsensor in Pocket, Implandata Looks to US

Now that the Implandata Ophthalmic Products has received approval to commercialize its implantable glaucoma-monitoring device in the European Union, it’s setting its sights on lining up funding to launch US trials in 2018, company managing director Max Ostermeier tells OIS Weekly in an exclusive podcast.

It’s no coincidence that the company’s initials – IOP – also are the abbreviation for intraocular pressure, which the firm’s implantable EYEMATE system monitors continually throughout the day. The EYEMATE system includes a permanent implantable microsensor that is placed in front of the artificial intraocular lens, posterior to the iris during cataract surgery.

The microsensor can measure the patient’s intraocular pressure at any chosen frequency, either continuously over the course of 24 hours or on demand at defined time points. Patients can perform measurement by themselves and under normal conditions. Collected data will be sent via a mobile phone module to the physician’s device, allowing remote monitoring and management of the patient’s disease and alerting of the physician to uncontrolled IOP.

For its US rollout, Implandata has already brought on renowned glaucoma specialist Robert N. Weinreb, MD, director of the Shiley Eye Institute at the University of California, San Diego, as scientific adviser. “Twenty-four-hour monitoring of intraocular pressure with an implantable sensor is transformative for management of glaucoma patients as it provides a plethora of data and deeper insight for enhanced management of their disease,” Dr. Weinreb says.

US trials also depend on financing and licensing, Ostermeier notes.

Implandata is also working on lining up Series C financing of up to 12 million Euros, part of which will fund activities in the US. The company is talking with strategic investors as part of its syndicate. “As small as we are right now, it would be really important for us to have a strategic partner to work within the US market,” he adds.

“Ideally we will close our funding round right at the summer of our funding rounds, and then we can start things in the US by end of the year and hopefully get our first study started in the US sometime in the second half of next year,” Ostermeier says.

In 2014, the company incorporated Implandata Ophthalmic Products Inc. in Delaware to gain a US foothold.

The current EYEMATE system version is CE marked for use in patients with primary open angle glaucoma. Implandata is also working on other versions to be used in other glaucoma conditions. The design team is also working on further miniaturization of the implant itself. “We want to get it very small so at the end you simply inject it into the anterior chamber or the posterior chamber into the sclera,” Ostermeier explains.

For the European market, Ostermeier says the company will focus on Germany, Austria, and Switzerland for commercial launch in the next 12 months.

SHARE THIS ARTICLE WITH YOUR COLLEAGUES:

RECOMMENDED FOR YOU

AbbVie’s Big Bet to Diversify with Allergan Pays Off So Far

AbbVie’s Big Bet to Diversify with Allergan Pays Off So Far

Eyenuk’s EyeArt AI System Showing Its Value

Eyenuk’s EyeArt AI System Showing Its Value

New J&J Vision CMO Steps onto a Very Large Stage

New J&J Vision CMO Steps onto a Very Large Stage

With Fresh Funding, Eyenovia Pursues Platform for Focused Drug Delivery

With Fresh Funding, Eyenovia Pursues Platform for Focused Drug Delivery

Covid-19 Impact on Healthcare Company Valuations & Financings

Covid-19 Impact on Healthcare Company Valuations & Financings

Aldeyra Eyes Lucrative DED, Conjunctivitis Markets

Aldeyra Eyes Lucrative DED, Conjunctivitis Markets

About The Author

Rich Kirkner

Richard Kirkner is an award-winning journalist and editorial consultant who has specialized in ophthalmology and eye care media for three decades. Based in Philadelphia, his work has been recognized with more than 40 awards for editorial excellence.

SUBSCRIBE TO OUR NEWSLETTER

Get The Latest News In Opthalmologic Innovation To Your Inbox.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

SUBSCRIBE TO OIS WEEKLY

Get our monthly newsletter about the latest in opthalmologic innovation.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

STAY CONNECTED

NEW VIDEOS

PODCASTS